Navigation Links
New Report Illuminates Ampligen's Unique Mechanism of Action

of dsRNAs for the induction of innate immunity. Unlike the toxic Poly I:Poly C, Ampligen is directed towards the activation of TLR-3 in the induction of innate immune responses.

The closely allied compound, Poly I : Poly C, has been used in clinical trials but has a broad range of side-effects, some of which are life-threatening. Where the studies found specific involvement of TLR-3 in conveying Ampligen(R)'s biologic properties, no such specificity was seen with poly I : poly C, thus explaining its side effect profile without compromising its potency as an immunotherapeutic.

The findings further establish the remarkable specificity of Ampligen(R) in activating the critical first line of defense against various types of pathogenic elements. The findings are pertinent to many cutting edge therapeutic topics in biotechnology today, including the enhancement of vaccine efficacy (both antiviral and anticancer) as well as strengthening biologic therapy (interferons, interleukins, etc.) of various serious human diseases as well as enhancing traditional antivirals such as Tamiflu(R) and Relenza(R).

The experimental therapeutic Ampligen(R) is perhaps the best studied TLR activator in human clinical trials to date, having been administered more than 75,000 times in approximately 15 clinical trials of which four were very well-controlled (placebo-controlled, randomized, multi-center, double-blinded).

"These scientific findings go a long way toward explaining how a single, relatively simple compound, Ampligen(R), can repeatedly show therapeutic promise in such a broad array of indications. The findings may also have broad economic implications for the American biotechnology sector," commented Dr. William A. Carter, Chairman and CEO of Hemispherx Biopharama, Inc. "According to a recent KPMG Bioscience report, our sector recently achieved a new high of $70 billion in revenues a year, but is now faced with many very short product life cycles, large po
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Report Illuminates Ampligen Unique Mechanism Action
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Products - Global Strategic Business Report" report to their ... for Anti-Adhesion Products in US$ Thousands by the following three ... Procedures. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. ... OMX First North Premier, Stockholm : "IMNP"), ... that its application to list its common stock on the ... Market, a unit of the NASDAQ OMX Group. IMMUNE,s common ... Market at the opening of trading on August 21, 2014 ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new market ... Russia Sinuscopes Market Outlook to 2020 ... Market Outlook to 2020 Summary ... 2020", provides key market data on the Russia Sinuscopes ... dollars, volume (in units) and average prices (in US ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:8/19/2014)... August 20, 2014 LunaDress, a popular ... cocktail dresses for ladies, is now providing a discount ... dresses . The company’s cheap white prom outfits are ... backless, and A-line outfits. , There are over ... product category, and the special offer is valid until ...
(Date:8/19/2014)... Los Angeles, CA (PRWEB) August 19, 2014 ... is an online training course designed to provide users ... businesses using proven email marketing techniques and strategies. The ... has created a buzz of excitement throughout the internet ... caught the attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, Aug. 19, ... infant has long been linked to development of asthma and ... risk may persist into the teen years. The study, ... underscores the dangers of parental smoking, experts say. ... a child,s risk of developing allergic disease even up to ...
(Date:8/19/2014)... Following the completion of a $16 million rooms renovation ... proud to debut the highly anticipated final phase of its ... of all public spaces to match the fresh look and ... dining experience at 1823 Kitchen and Bar and an innovative ... of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay has ...
(Date:8/19/2014)... Program has selected three geriatric social work ... development and mentorship for projects that will improve ... for all older adults. , The 2014 Hartford/VA ... among veterans, transitions from VA nursing facilities back ... older veterans. The Hartford/VA Geriatric Scholars Program provides ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2
... Oct. 4 The following is a,statement regarding Microsoft,s ... information online:, It is encouraging that companies like ... health record (PHR) products and systems,that people can use ... companies will follow suit. Having ready access to your ...
... Orr, fired for managing diabetes at work but ... Thursday before House Judiciary,Subcommittee about his experience, ... today reiterated its strong support for the ADA,Restoration ... the landmark,1990 Americans with Disabilities Act. On Thursday, ...
... ACTON, Mass., Oct. 4 Psychemedics Corporation,(AMEX: ... joined the company,as Vice President, Controller. Jennifer ... financial,reporting activities, as well as the financial analysis ... Jennifer will,report directly to the Chairman and CEO. ...
... Connector, provides patients with virtual diabetes health- ... management ... Association today unveiled a new web-based diabetes tool that,makes it ... -- to,share and organize important health information to improve their ...
... BOSTON, Oct. 4 Diet.com has joined ... of the newly launched Microsoft,HealthVault consumer health ... which currently include,Diet.com Calorie/Meal Tracker, Diet.com Weight ... incorporated into HealthVault. The trackers will,enable users ...
... Oct. 4 Genta,Incorporated (Nasdaq: GNTA ) announced ... Raymond P. Warrell, Jr., will provide an,update of corporate ... 10th at 2:15 pm PDT. The conference will be ... The presentation will be webcast and accessible at the ...
Cached Medicine News:Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 3Health News:Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 3Health News:New Diabetes Tool Available on American Diabetes Association Web Site 4Health News:Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 3
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Glaucoma Laser System features a patented technique ... glaucoma. It selectively targets pigmented cells and ... Selecta II is equipped with a Q-switch ... light, which induces the same cell replacement ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: